mact
OK, I might agree with you that the pps could double, but for which company? Or do you really believe both of them would double? I know that SPPI gets royalties of 10% and that GPCB would be the main beneficiary of approval (they now own the drug, although I understand it's being contested by SPPI - maybe they just want a bigger percentage in the way of royalties since they screwed up in "giving" it away) - but I'm not sure if I would think that both might double. Care to provide your rationale on the double and which company, or why both?